Physician profile
David Lindner
NPI 1124064449
$37,569.54
in general payments reported to CMS, 2019-2025
28 companies · $5,453 in 2025
The $5,453 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $692 · 2021: $510 · 2022: $10K · 2023: $12K · 2024: $8,067 · 2025: $5,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,090 · Education: $6,100 · Food and Beverage: $5,322 · Consulting Fee: $2,630 · Travel and Lodging: $2,466 · Gift: $23.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,090.00 |
| Education | $6,099.95 |
| Food and Beverage | $5,322.03 |
| Consulting Fee | $2,630.00 |
| Travel and Lodging | $2,465.91 |
| Gift | $23.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $18,929.11 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Intuitive Surgical, INC. | $9,028.22 | 2024-2025 | |
| Pulmonx Corporation | $3,652.77 | 2022-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Ethicon INC. | $1,479.26 | 2022-2023 | Monarch Platform |
| Merck Sharp & Dohme LLC | $1,035.32 | 2023-2025 | Winrevair |
| United Therapeutics Corporation | $706.68 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Glaxosmithkline, LLC. | $606.96 | 2020-2024 | Nucala, Arexvy, Trelegy Ellipta |
| Insmed, INC. | $431.72 | 2020-2025 | Arikayce |
| Astrazeneca Pharmaceuticals Lp | $424.99 | 2021-2024 | Tezspire |
| Johnson & Johnson Health Care Systems INC. | $169.97 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $164.37 | 2021-2022 | |
| Grifols Shared Services North America, INC. | $149.27 | 2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $109.62 | 2025 | Zepbound |
| Medtronic, INC. | $107.52 | 2022-2025 | Nuvent, Illumisite |
| Galvanize Therapeutics, INC | $94.63 | 2025 | Aliya System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $92.45 | 2025 | Photofrin |
| Abiomed | $80.25 | 2025 | |
| Sandoz INC. | $61.42 | 2023 | Treprostinil |
| Alnylam Pharmaceuticals INC. | $44.69 | 2022-2023 | Onpattro |
| Boston Scientific Corporation | $38.37 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $33.86 | 2025 | Acthar |
| Genentech USA, INC. | $27.51 | 2022 | |
| Philips North America LLC | $26.17 | 2022 | |
| Paratek Pharmaceuticals, INC. | $23.86 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.32 | 2021 | |
| Covidien Lp | $19.30 | 2019 | |
| Abbott Laboratories | $10.93 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lindner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.